Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2017
Agenda for the December 2017 PBAC meeting
4 October 2017 - The agenda for the December 2017 PBAC meeting, to be held on 15 December 2017, is ...
Posted by Michael Wonder on 04 Oct 2017
Proposal to list a range of medical thermometer products and medical devices used in the prevention of venous thromboembolisms supplied by Medtronic
4 October 2017 - PHARMAC is seeking feedback on a proposal to list a range of medical thermometer and venous thromboembolism ...
Posted by Michael Wonder on 02 Oct 2017
Revised procedure for advance notification of pending CDR submissions and resubmissions
28 September 2017 - In September 2016, CADTH updated the advance notification procedure for the Common Drug Review. ...
Posted by Michael Wonder on 02 Oct 2017
Why is Keytruda funded for melanoma, but not lung cancer?
1 October 2017 - Is it fair that melanoma gets funded for a particular drug while lung cancer doesn't? ...
Posted by Michael Wonder on 30 Sep 2017
Blacked-out information reveals secret world of drug prices
30 September 2017 - This week, the Patented Medicine Prices Review Board ruled the Canadian price of the drug Soliris is ...
Posted by Michael Wonder on 30 Sep 2017
Improved access? The reality of the PPRS
29 September 2017 - In the third in her series of five articles, Leela Barham considers the extent to which ...
Posted by Michael Wonder on 30 Sep 2017
Schedule of Pharmaceutical Benefits - 1 October 2017 update
1 October 2017 - The October 2017 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Sep 2017
New Zealand Pharmaceutical Schedule - 1 October 2017
1 October 2017 - The October 2017 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Sep 2017
Advance notice of a request for proposals - permanent coronary drug-eluting stents
29 September 2017 - PHARMAC is interested in receiving proposals for dual and/or sole supply market share of permanent coronary ...
Posted by Michael Wonder on 29 Sep 2017
Prescription medicine for cancer, cholesterol and contraception is about to get cheaper
30 September 2017 - The price of more than 1400 medicines including the nation’s biggest selling drug the anti-cholesterol pill ...
Posted by Michael Wonder on 29 Sep 2017
Price deal sees NICE back Imbruvica for one indication but not another
28 September 2017 - The UK’s NICE has recommended Imbruvica (ibrutinib), within its marketing authorisation, for use on the Cancer ...
Posted by Michael Wonder on 28 Sep 2017
Canadian regulator orders price cut of expensive U.S. drug Soliris
27 September 2017 - The maker of the one of the world's most expensive drugs has been ordered to slash ...
Posted by Michael Wonder on 28 Sep 2017
NICE knocks-back Janssen's Imbruvica in Mantle cell lymphoma
28 September 2017 - Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib). ...
Posted by Michael Wonder on 27 Sep 2017
New advance value framework offered as a decision-support tool for reimbursement
25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision ...
Posted by Michael Wonder on 27 Sep 2017
NZ behind rest of modern world in medicines funding
21 September 2017 - New Zealand is lagging behind the rest of the modern world when it comes to funding ...